Tired of ads interrupting your gripping investigations? Good news!

Ad-free listening on Amazon Music is included with your Prime Membership.

Ads shouldn't be the scariest thing about true crime podcasts.

To start listening, download the Amazon Music app or visit amazon.co.uk forward slash true crime ad-free.

That's amazon.co.uk forward slash true crime ad-free to catch up on the latest episodes, without the ads.

Hi everybody, Cheryl Ackison here. Welcome to another edition of Full Measure After Hours.

Today, could the first cure for Alzheimer's be on the horizon? Or is it just a mirage?

I think the cover story this week on Full Measure and what we're going to talk about in the podcast

is really important subject matter that could impact millions and millions of people.

We're talking about a possible cure for early Alzheimer's disease, the early stages.

But like everything these days, it seems nothing is really that simple or that easy.

While this could be super promising and important to millions and millions of people,

there are a lot of questions about whether it really works, how much it could cost,

the FDA's actions in some instances with the company that makes the drug. We're going to look at all of that.

Now first, a couple of the basics. I looked up how many people it's estimated in the United States

have Alzheimer's disease. And according to the CDC in 2020, as many as 5.8 million Americans

were living with Alzheimer's disease. Younger people, says CDC, may rarely get Alzheimer's disease,

but it's not too common. It is considered the most common type of dementia. So when you talk about

dementia, it's one form of it. Not all dementia is Alzheimer's disease, but all Alzheimer's disease

is considered dementia. And CDC says it's a progressive disease that begins with mild memory loss

and possibly leads to the loss of the ability to carry on normal conversations, respond to people

the normal way. Alzheimer's disease is said to involve the parts of the brain that control thought

...